| Rachele Parente, | |
|
803 Brightseat Road, Landover, MD 20785 | |
| (301) 333-2980 | |
| Not Available |
| Full Name | Rachele Parente |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 803 Brightseat Road, Landover, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407448194 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 0903003077 (Virginia) | Secondary |
| 1041C0700X | Social Worker - Clinical | 26272 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rachele Parente, 903 Brightseat Rd, Landover, MD 20785-4725 Ph: () - | Rachele Parente, 803 Brightseat Road, Landover, MD 20785 Ph: (301) 333-2980 |
News Archive
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company's world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.
Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.
After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.
The systemic use of heparin for treating severe coronavirus disease (COVID-19) showed significant improvements in oxygen exchange and overall clinical presentation of patients, as reported by a study from Brazil available on a preprint server medRxiv.
› Verified 5 days ago
Kamika Pope, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1103 Consideration Ln, Landover, MD 20785 Phone: 443-414-4619 | |
Theodore Michener, LCSW-C Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 903 Brightseat Rd, Landover, MD 20785 Phone: 301-333-2980 | |
Eboni Henry, LGSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 411 Warfield Dr, Apt 3008, Landover, MD 20785 Phone: 706-340-6521 | |
Anita Lewis, LCSWC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8181 Professional Pl Ste 200, Landover, MD 20785 Phone: 301-306-4590 Fax: 301-880-0054 | |
Mrs. Regina Miller Nadir, LCSW-C, LICSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 8201 Corporate Dr Ste 500, Landover, MD 20785 Phone: 301-758-7058 Fax: 301-218-7358 | |
Pauline Boldin, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8100 Professional Pl Ste 200, Landover, MD 20785 Phone: 301-577-4470 | |
Marissa Frumento, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6501 Columbia Park Rd, Landover, MD 20785 Phone: 301-925-1360 |